Study Update: First Advanced BCC Patient Treated With SP-002 in Plus Vismodegib in New Phase 2 Study
The first patient has been treated in Stamford Pharmaceuticals Inc.’s trial of SP-002, an adenoviral-based immunotherapy, and vismodegib (Erivedge, Roche) in locally advanced basal cell carcinoma (laBCC). Vismodegib is a hedgehog Pathway inhibitor (HHPI) that is approved for the treatment of adult patients presenting with locally advanced and metastatic basal cell carcinoma. SP-002 has been engineered […]